Search

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globally Combined in-licensing and financing for a novel long-acting clinical stage monoclonal antibody [...]

ROYAL OAK, Mich., Jan. 7, 2025 /PRNewswire/ -- Parallel ENT & Allergy has added https://c212.net/c/link/?t=0&l=en&o=4330682-1&h=885763712&u=https%3A%2F%2Fwww.allergyctr.com%2F&a=Allergy+%26+Asthma+Associates+of+Michigan as a Parallel supported practice. Parallel will provide non-clinical, practice management services to provide the [...]

- Funding secured from CF Foundation and current investors for SPL84 Phase 2 study - - Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 [...]

WASHINGTON, Feb. 25, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as 'Longbio Pharma'), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, [...]

Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture Partners Proceeds to advance AER-01 into the clinic for treatment of chronic obstructive pulmonary disease (COPD); unique targeted [...]

Asthma is a chronic disease that affects a substantial number of patients worldwide, including children, a number of pharmaceutical companies are involved in developing drugs for asthma. This involvement includes [...]

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3775499-1&h=1424136920&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&a=Pulmatrix%2C+Inc.(NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE(TM) technology, today announced the first [...]

DUBLIN, Jan. 6, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5671197/connected-drug-delivery-devices-market-by-type?utm_source=CI&utm_medium=PressRelease&utm_code=g2dm79&utm_campaign=1802541+-+The+Worldwide+Connected+Drug+Delivery+Devices+Industry+is+Expected+to+Reach+%242+Billion+by+2030&utm_exec=jamu273prd report has been added toResearchAndMarkets.com's offering. The global connected drug delivery devices market is envisioned to garner $2,095.2 million by 2030, growing [...]

BEIJING, Dec. 14, 2022 /PRNewswire/ -- Severe asthma, a much more complicated form of asthma, requires treatment with a high dose of steroid-based anti-inflammatory medications (also known as inhaled corticosteroids [...]

Results from Phase III trials conducted by Avillion in over 4,000 patients show that PT027, a novel fixed-dose combination of albuterol and budesonide, significantly reduced the risk of a severe [...]

VIENNA, Va., May 2, 2022 /PRNewswire/ -- With more than 24 million Americans living with asthma and 50+ million with allergies, it's vital they have greater access to medical care [...]

BOSTON, April 5, 2022 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), and AstraZeneca have published results from their ZEPHYR 1 study, [...]

Analyses From NAVIGATOR and PATHWAY Trials Presented at the 2022 AAAAI Annual Meeting THOUSAND OAKS, Calif., Feb. 26, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc [...]

Asthma and bronchiectasis patients with chronic rhinosinusitis are associated with increased healthcare utilization according to research from the 2022 AAAAI Annual Meeting. Milwaukee, WI, Feb. 1, 2022 /PRNewswire-PRWeb/ -- Chronic [...]

Integrating data from the Propeller platform into Dignity Health's EHR improves clinical and operational efficiencies and provides physicians with real-time insights to improve patient treatment decisions SAN FRANCISCO, Oct. 5, [...]

Improvements Also Demonstrated in Lung Function and Nasal Polyp Symptoms Exploratory Analysis From NAVIGATOR Phase 3 Trial Presented at European Respiratory Society (ERS) International Congress 2021 THOUSAND OAKS, Calif., Sept. [...]

Tezepelumab is the First and Only Biologic to Consistently and Significantly Reduce Asthma Exacerbations in a Broad Population of Patients Across Phase 2 and 3 Clinical Trials THOUSAND OAKS, Calif., [...]

The largest NP and PA network in the U.S. joins forces with NHLBI and others to raise awareness of new treatments and therapies in pulmonary care PARSIPPANY, N.J., May 6, [...]

Data From Investigational Therapy Tezepelumab Phase 3 NAVIGATOR Trial in Patients With Severe Asthma Presented at the American Academy of Asthma Allergy & Immunology Annual Meeting THOUSAND OAKS, Calif., Feb. [...]

According to research scheduled for presentation at the 2021 AAAAI Virtual Annual Meeting, which takes place February 26-March 1, wearing a mask can help slow the spread of COVID-19 and [...]

THOUSAND OAKS, Calif., Dec. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the [...]

AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat [...]

Highmark announced that it has entered an outcomes-based agreement with AstraZeneca for Fasenra, an add-on prescription maintenance treatment for patients age 12 or older with severe asthma. Through outcomes-based agreements, [...]

New document summarizes the current overall recommendations for treating students with asthma at school during the ongoing pandemic. MILWAUKEE, Wis., Aug. 27, 2020 /PRNewswire-PRWeb/ -- The American Academy of Allergy, [...]

- Once-daily Enerzair Breezhaler (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily Tio in improving quality of life in people with uncontrolled [...]

Real-world data shows patients have low persistence rates EAGAN, Minn., April 16, 2020 /PRNewswire/ -- New research from Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving more than [...]

Circulaire ll Aerosol Drug Delivery System mitigates healthcare workers' exposure to contagions like coronavirus, while optimizing medication delivery for patients* TUCSON, Ariz., April 14, 2020 /PRNewswire/ -- In today's unprecedented [...]

MONTREAL, March 18, 2020 /PRNewswire/ - Pharmascience Inc. is proud to bring to market a new product for the maintenance treatment of asthma and COPD. pms-FLUTICASONE PROPIONATE/SALMETEROL DPI, a generic [...]

Hoth appoints Dr. Glenn Cruse, formerly of the NIH and a leading mast cell biologist in allergic and inflammatory diseases, to the Scientific Advisory Board NEW YORK, Feb. 4, 2020 [...]

Phase 2 clinical trial initiated and enrollment progressing across 24 sites Study to support proof-of-concept mechanism with top line data expected mid-2020 LEXINGTON, Mass., Sept. 18, 2019 /PRNewswire/ -- Pulmatrix, [...]

LEEDS, England, July 8, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on its lead Live Biotherapeutic [...]

TARRYTOWN, N.Y. and PARIS, March 1, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use [...]

Unique Pricing of Wixela Inhub Immediately Benefits Patients and Reduces Overall Cost to the U.S. Healthcare System HERTFORDSHIRE, England and PITTSBURGH, Feb. 12, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) [...]

The doctors and providers at San Tan Allergy & Asthma have worked hard over the past several months to open a new clinic, Arcadia Allergy & Asthma. This new clinic [...]

Walgreens is the first to be included in the new My Pharmacy feature MADISON, Wis., Jan. 9, 2019 /PRNewswire/ -- Propeller Health, a leading digital therapeutics company, today announced My [...]

- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery - Dupixent has now demonstrated positive late-stage results in three Type 2 or [...]

TARRYTOWN, N.Y. and PARIS, Oct. 16, 2018 /PRNewswire/ -- Dupixent significantly reduced nasal polyp size, nasal congestion severity and need for systemic corticosteroids and/or surgery Dupixent has now demonstrated positive [...]

Designation Supported by Phase 2b PATHWAY Data That Demonstrated Tezepelumab Significantly Reduced Asthma Exacerbations Compared to Placebo in Severe Asthma Patients THOUSAND OAKS, Calif., Sept. 6, 2018 /PRNewswire/ -- Amgen [...]

Members include experts in both clinical research and management of Allergic Bronchopulmonary Aspergillosis and Asthma LEXINGTON, Mass., July 23, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical [...]

TARRYTOWN, N.Y. and PARIS, May 21, 2018 /PRNewswire/ -- Results showed DUPIXENT demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population [...]

TARRYTOWN, N.Y. and PARIS, April 3, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) and Sanofi today announced that the European Medicines Agency (EMA) has accepted for review an application [...]

TARRYTOWN, N.Y. and PARIS, March 2, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review [...]

MADISON, Wis., Feb. 8, 2018 /PRNewswire/ -- Propeller Health, the leading digital solution for respiratory medicine, has been awarded International Organization for Standardization (ISO) 13485:2016 certification for medical device quality [...]

Growing Emphasis on Adherence and Adaptive Learning are Key Drivers in this Market According to Greystone Research Associates AMHERST, N.H., Nov. 27, 2017 /PRNewswire/ -- Converging technologies are creating new [...]

MUMBAI, Baltimore, May 31, 2017 /PRNewswire/ -- Today, Pharma Major Lupin Limited announced a partnership between its American subsidiary, Lupin Pharmaceuticals, Inc. (Lupin) and Albertsons Companies, one of the largest [...]

Results from Evaluation of Real-World Patients Presented at American Thoracic Society International Conference MARLBOROUGH, Mass., May 24, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced positive results from the [...]

Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva DUBLIN, Dec. 19, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. [...]

FDA Approved, Low-cost Treatment for Patients who Require Epinephrine Auto-Injection, Available Now HAYWARD, Calif., Oct. 31, 2016 /PRNewswire/ -- WHAT: There is ongoing concern regarding price increases of pharmaceutical products. [...]

Partnership harnesses video medicine to improve allergy and asthma care SAN FRANCISCO, April 20, 2016 /PRNewswire-USNewswire/ -- Today http://www.doctorondemand.com/ , the leading U.S. video medicine provider, announced a new partnership [...]

SPIRIVA RESPIMAT shown effective in the broad range of asthma patients studied who continued to experience symptoms despite taking other asthma maintenance therapies New analyses show improved lung function* and [...]